

# Pedro M Machado Frcp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6420729/publications.pdf>

Version: 2024-02-01

268  
papers

11,210  
citations

44069

48  
h-index

34986

98  
g-index

306  
all docs

306  
docs citations

306  
times ranked

10352  
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry"™ by Arnaud and Devilliers. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e114-e114.	0.9	2
2	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry"™ by Mulhearn <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e116-e116.	0.9	87
3	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry"™ by Rosenbaum <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e139-e139.	0.9	2
4	Response to: "Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry"™ by Sparks <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e158-e158.	0.9	3
5	Response to: "Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis"™ by van Vollenhoven <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e178-e178.	0.9	7
6	COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database. <i>Brain</i> , 2023, 146, 739-748.	7.6	57
7	Correspondence on "Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment"™. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e183-e183.	0.9	3
8	Instrument selection for the ASAS core outcome set for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 763-772.	0.9	18
9	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry™ by Gianfrancesco <i>et al</i> . <i>Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases</i> ™ by Giollo <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2023, 81, 223-223.	0.9	5
10	Long-term Association Between Disease Activity and Disability in Early Axial Spondyloarthritis: Results From a Prospective Observational Study of Inflammatory Back Pain. <i>Arthritis Care and Research</i> , 2022, 74, 768-775.	3.4	11
11	SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 145-150.	0.9	30
12	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2022, 49, 110-114.	2.0	9
13	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 34-40.	0.9	26
14	Rapid Adoption of Telemedicine in Rheumatology Care During the COVID-19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees. <i>ACR Open Rheumatology</i> , 2022, 4, 128-133.	2.1	6
15	Correspondence on "Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C-reactive protein level and patient global assessment"™ by Felson <i>et al</i> . <i>ACR Open Rheumatology</i> , 2022, 4, 271-272.	2.1	1
16	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 780-785.	0.9	12
17	Reexamining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C-reactive protein level, and patient global assessment: comment on the article by Felson <i>et al</i> . <i>Arthritis Care and Research</i> , 2022, 74, 501-502.	3.4	0
18	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>Lancet Rheumatology</i> , The, 2022, 4, e237-e240.	3.9	30

#	ARTICLE	IF	CITATIONS
19	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 695-709.	0.9	130
20	Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 422-432.	0.9	75
21	The impact of COVID-19 on rheumatology training—results from the COVID-19 Global Rheumatology Alliance trainee survey. <i>Rheumatology Advances in Practice</i> , 2022, 6, rrac001.	0.7	7
22	Rituximab in rheumatology: single-centre SARS-CoV-2 infection and COVID-19 prevalence. <i>Rheumatology Advances in Practice</i> , 2022, 6, rrac009.	0.7	1
23	Measuring change in inclusion body myositis: clinical assessments versus imaging. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 404-413.	0.8	6
24	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.9	49
25	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1628-1639.	0.9	89
26	Measuring quality of life of patients with axial spondyloarthritis for economic evaluation. <i>RMD Open</i> , 2022, 8, e001955.	3.8	2
27	COVID-19-Related Outcomes in Primary Mitochondrial Diseases. <i>Neurology</i> , 2022, 98, 576-582.	1.1	7
28	Axial spondyloarthritis. <i>Medicine</i> , 2022, 50, 159-166.	0.4	2
29	Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 998-1005.	0.9	12
30	British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2022, 61, 1760-1768.	1.9	37
31	EULAR points to consider for the use of imaging to guide interventional procedures in patients with rheumatic and musculoskeletal diseases (RMDs). <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 760-767.	0.9	9
32	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. <i>Rheumatology</i> , 2022, 61, SI143-SI150.	1.9	40
33	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187.	3.8	34
34	Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis.. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 384-393.	0.8	0
35	Measuring change in inclusion body myositis: clinical assessments versus imaging.. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 404-413.	0.8	0
36	OA01—Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Rheumatology</i> , 2022, 61, .	1.9	0

#	ARTICLE	IF	CITATIONS
37	MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1243-1251.	0.9	22
38	Longitudinal Changes in MRI Muscle Morphometry and Composition in People With Inclusion Body Myositis. <i>Neurology</i> , 2022, 99, .	1.1	7
39	Response to: "Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis" by Gyrfi et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e88-e88.	0.9	8
40	Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable. <i>Rheumatology</i> , 2021, 60, 638-648.	1.9	9
41	Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. <i>Arthritis and Rheumatology</i> , 2021, 73, 374-380.	5.6	66
42	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 518-526.	0.9	54
43	The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. <i>Rheumatology</i> , 2021, 60, 353-358.	1.9	32
44	Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 293-303.	0.9	32
45	Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. <i>Brain</i> , 2021, 144, 682-693.	7.6	221
46	Rheumatic disease and COVID-19: epidemiology and outcomes. <i>Nature Reviews Rheumatology</i> , 2021, 17, 71-72.	8.0	120
47	Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies. <i>Rheumatology and Therapy</i> , 2021, 8, 273-288.	2.3	11
48	Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. <i>RMD Open</i> , 2021, 7, e001450.	3.8	64
49	Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 803-815.	0.9	31
50	Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001549.	3.8	14
51	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 698-706.	0.9	37
52	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2021, 60, 2615-2628.	1.9	69
53	Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis. <i>Neurology</i> , 2021, 96, e1595-e1607.	1.1	25
54	Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility. <i>Rheumatology</i> , 2021, 60, 4778-4789.	1.9	44

#	ARTICLE	IF	CITATIONS
55	Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101657.	3.3	28
56	Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. <i>Rheumatology International</i> , 2021, 41, 1021-1036.	3.0	52
57	Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 854-862.	1.9	15
58	Axial Spondyloarthritis: Mimics and Pitfalls of Imaging Assessment. <i>Frontiers in Medicine</i> , 2021, 8, 658538.	2.6	13
59	SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. <i>Lancet Rheumatology</i> , The, 2021, 3, e481-e488.	3.9	25
60	EULAR COVID-19 registry: lessons learnt and future considerations. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1110-1115.	0.9	6
61	OP0287â€¦IMMUNOMODULATORY THERAPIES FOR SEVERE FORMS OF COVID-19: A SYSTEMATIC LITERATURE REVIEW TO INFORM EULAR POINTS TO CONSIDER. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 175.1-175.	0.9	0
62	OP0286â€¦CHARACTERISTICS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (COVID-19 GRA). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 173.2-175.	0.9	1
63	LB0002â€¦COVID-19 VACCINE SAFETY IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 199-200.	0.9	21
64	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.9	151
65	AB0674â€¦RAPID ADOPTION OF TELEMEDICINE IN RHEUMATOLOGY TRAINING: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE TRAINEE SURVEY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1368.3-1369.	0.9	0
66	POS0051â€¦THE IMPACT OF COVID-19 ON RHEUMATOLOGY TRAINING: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE TRAINEE SURVEY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 230.2-231.	0.9	0
67	POS0238â€¦SICK LEAVE AND ITS PREDICTORS IN EARLY AXIAL SPONDYLOARTHRITIS: THE ROLE OF CLINICAL AND SOCIOECONOMIC FACTORS. FIVE-YEAR DATA FROM THE DESIR COHORT. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 340.2-340.	0.9	0
68	POS0952â€¦RESPONSIVENESS OF SPINAL MOBILITY MEASUREMENTS IN AXIAL SPONDYLOARTHRITIS USING CONVENTIONAL AND ADVANCED METROLOGY: A PILOT STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 740.1-740.	0.9	0
69	OP0047â€¦IDENTIFICATION OF CLINICAL PHENOTYPES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, PERIPHERAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS ACCORDING TO PERIPHERAL MUSCULOSKELETAL MANIFESTATIONS: A CLUSTER ANALYSIS IN THE INTERNATIONAL ASAS-PERSPA STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 24.2-25.	0.9	0
70	POS1183â€¦OUTCOMES OF COVID-19 INFECTION AMONG CHILDREN AND YOUNG PEOPLE WITH PRE-EXISTING RHEUMATIC AND MUSCULOSKELETAL DISEASES. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 872.2-873.	0.9	2
71	OP0288â€¦MACHINE LEARNING ALGORITHMS TO PREDICT COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME IN PATIENTS WITH RHEUMATIC DISEASES: RESULTS FROM THE GLOBAL RHEUMATOLOGY ALLIANCE PROVIDER REGISTRY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 175.2-176.	0.9	1
72	POS0055â€¦SARS-COV-2 OUTBREAK IN AUTOIMMUNE DISEASES: THE EURO-COVIMID STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 233-234.	0.9	1

#	ARTICLE	IF	CITATIONS
73	POS0052â€¦.PATHOPHYSIOLOGY OF ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION: A SYSTEMATIC LITERATURE REVIEW TO INFORM EULAR POINTS TO CONSIDER. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 231-232.	0.9	0
74	The Early History of Arimoclomol for Inclusion Body Myositis. <i>RRNMF Neuromuscular Journal</i> , 2021, 2, .	0.1	1
75	Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort. <i>RMD Open</i> , 2021, 7, e001685.	3.8	6
76	The ASAS-OMERACT core domain set for axial spondyloarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1342-1349.	3.4	35
77	The Effect of ACTN3 and VDR Polymorphisms on Skeletal Muscle Performance in Axial Spondyloarthropathies. <i>Frontiers in Genetics</i> , 2021, 12, 688984.	2.3	1
78	Phase II Study of Arimoclomol in IBM FDA-OOPD. <i>RRNMF Neuromuscular Journal</i> , 2021, 2, .	0.1	0
79	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , 2021, 7, e001814.	3.8	121
80	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology</i> , The, 2021, 3, e707-e714.	3.9	40
81	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942.	0.9	496
82	Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. <i>Current Opinion in Rheumatology</i> , 2021, 33, 111-116.	4.3	12
83	Mitochondrial disease and COVID-19: An international cohort study confirms risks and long-term outcomes. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119358.	0.6	0
84	A crossâ€¦sectional study of memory and executive functions in patients with sporadic inclusion body myositis. <i>Muscle and Nerve</i> , 2021, 65, 105.	2.2	0
85	Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001899.	3.8	8
86	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	5.9	86
87	Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study. <i>RMD Open</i> , 2021, 7, e001728.	3.8	5
88	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e855-e864.	3.9	38
89	Value of imaging to guide interventional procedures in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001864.	3.8	6
90	Current Practice of Imaging-Guided Interventional Procedures in Rheumatic and Musculoskeletal Diseases: Results of a Multinational Multidisciplinary Survey. <i>Frontiers in Medicine</i> , 2021, 8, 779975.	2.6	3

#	ARTICLE	IF	CITATIONS
91	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. RMD Open, 2021, 7, e001818.	3.8	4
92	EMerging EULAR NETwork (EMEUNET): a remarkable foundation for the future. RMD Open, 2021, 7, e001962.	3.8	1
93	Association of 17 Definitions of Remission with Functional Status in a Large Clinical Practice Cohort of Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2020, 47, 20-27.	2.0	3
94	Inhibition of interleukin-17 in axial spondyloarthritis spectrum. Lancet, The, 2020, 395, 6-8.	13.7	2
95	Determining factors related to impaired spinal and hip mobility in patients with axial spondyloarthritis: longitudinal results from the DESIR cohort. RMD Open, 2020, 6, e001356.	3.8	8
96	P263 Should we advocate biologic dose-reduction in patients with AxSpA?. Rheumatology, 2020, 59, .	1.9	0
97	Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study. Rheumatology Advances in Practice, 2020, 4, rkaa015.	0.7	3
98	Measuring Spinal Mobility Using an Inertial Measurement Unit System: A Validation Study in Axial Spondyloarthritis. Diagnostics, 2020, 10, 426.	2.6	20
99	Differential Diagnoses of Inclusion Body Myositis. Neurologic Clinics, 2020, 38, 697-710.	1.8	1
100	COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: "Correspondence on "Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry" by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials " a real-world district general hospital experience" by K. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-218713.	0.9	11
101	No relationship between bone mineral density and syndesmophyte formation at the same level in the lumbar spine of patients with radiographic axial Spondyloarthritis. RMD Open, 2020, 6, e001391.	3.8	6
102	The diagnostic role of diffusional kurtosis imaging in glioma grading and differentiation of gliomas from other intra-axial brain tumours: a systematic review with critical appraisal and meta-analysis. Neuroradiology, 2020, 62, 791-802.	2.2	23
103	Capturing Patient-Reported Outcomes During the COVID-19 Pandemic: Development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey. Arthritis Care and Research, 2020, 72, 871-873.	3.4	25
104	Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria. Annals of the Rheumatic Diseases, 2020, 79, 935-942.	0.9	14
105	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases, 2020, 79, 859-866.	0.9	908
106	Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Annals of the Rheumatic Diseases, 2020, 79, 1386-1388.	0.9	67
107	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Annals of the Rheumatic Diseases, 2020, 79, 851-858.	0.9	204
108	Classification Criteria in Axial Spondyloarthritis. Rheumatic Disease Clinics of North America, 2020, 46, 259-274.	1.9	14

#	ARTICLE	IF	CITATIONS
109	Validity and reliability of a sensor-based electronic spinal mobility index for axial spondyloarthritis. <i>Rheumatology</i> , 2020, 59, 3415-3423.	1.9	10
110	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , The, 2020, 2, e250-e253.	3.9	172
111	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 193-201.	0.9	59
112	FRI0317â€¦...CONSENSUS DEFINITIONS FOR MRI LESIONS IN THE SPINE OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: FIRST ANALYSIS FROM THE ASSESSMENTS IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY CLASSIFICATION COHORT. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 749.2-750.	0.9	2
113	Recent advances in managing axial spondyloarthritis. <i>F1000Research</i> , 2020, 9, 697.	1.6	6
114	Conducting research in a pandemic: The power of social media. <i>European Journal of Rheumatology</i> , 2020, 7, S85-S88.	0.6	10
115	OP0079â€¦...PRELIMINARY DEFINITION OF A POSITIVE MRI FOR STRUCTURAL LESIONS IN THE SACROILIAC JOINTS IN AXIAL SPONDYLOARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 53-54.	0.9	1
116	OP0060â€¦...MACHINE LEARNING BASED BERLIN SCORING OF MAGNETIC RESONANCE IMAGES OF THE SPINE IN PATIENTS WITH ANKYLOSING SPONDYLITIS FROM THE MEASURE 1 STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 40-41.	0.9	1
117	FRI0302â€¦...WHAT IS THE IMPACT OF DISCREPANCY BETWEEN CENTRAL AND LOCAL READERS IN EVALUATION OF MRI SCANS ON THE CLASSIFICATION OF AXIAL SPONDYLOARTHRITIS? DATA FROM THE ASAS CLASSIFICATION COHORT STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 740.2-741.	0.9	0
118	OP0198â€¦...A SYSTEMATIC REVIEW TO INFORM THE EULAR POINTS TO CONSIDER WHEN ANALYSING AND REPORTING COMPARATIVE EFFECTIVENESS RESEARCH WITH OBSERVATIONAL DATA IN RHEUMATOLOGY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 123.2-124.	0.9	1
119	OP0008â€¦...DEVELOPMENT AND VALIDATION OF AN ALTERNATIVE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE WHEN PATIENT GLOBAL ASSESSMENT IS UNAVAILABLE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 6-6.	0.9	21
120	AB1083â€¦...CURRENT PRACTICE AND OPINIONS ON IMAGING-GUIDED INTERVENTIONAL PROCEDURES IN RHEUMATIC AND MUSCULOSKELETAL DISEASES: INTERIM RESULTS OF A MULTINATIONAL MULTIDISCIPLINARY SURVEY TO INFORM EULAR POINTS TO CONSIDER. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1830.2-1831.	0.9	1
121	OP0199â€¦...POINTS TO CONSIDER WHEN ANALYSING AND REPORTING COMPARATIVE EFFECTIVENESS RESEARCH WITH OBSERVATIONAL DATA IN RHEUMATOLOGY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 124-125.	0.9	2
122	SAT0332â€¦...ANTIBODIES AGAINST CYTOSOLIC 5â€¦™-NUCLEOTIDASE 1A IN SPORADIC INCLUSION BODY MYOSITIS: ASSOCIATION WITH CLINICAL AND MRI FEATURES. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1112.1-1112.	0.9	0
123	OP0078â€¦...MAPPING FROM THE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE (ASDAS) TO EQ5D IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 52.1-53.	0.9	0
124	SAT0384â€¦...REPLACEMENT OF RADIOGRAPHIC SACROILITIS BY MRI STRUCTURAL LESIONS: WHAT IS THE IMPACT ON CLASSIFICATION OF AXIAL SPONDYLOARTHRITIS IN THE ASAS CLASSIFICATION COHORT?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1140.2-1141.	0.9	0
125	Educational needs in people with ankylosing spondylitis and psoriatic arthritis: a cross-sectional study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 282-288.	0.8	1
126	The European Portuguese version of the ASAS Health Index for Patients with Spondyloarthritis: Measurement properties. <i>Acta ReumatolÃ³gica Portuguesa</i> , 2020, 45, 26-33.	0.2	1



#	ARTICLE	IF	CITATIONS
127	Development and validation of psoriatic arthritis switch quality assessment tool (PASQAL) - an outcomes measurement tool to assess the quality of biologic switch decisions in psoriatic arthritis. Acta Reumatol <sup>3</sup> gica Portuguesa, 2020, 45, 46-57.	0.2	0
128	Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, e109-e109.	0.9	35
129	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurology, The, 2019, 18, 834-844.	10.2	91
130	P.02Phase 2/3 study of Arimoclomol in sporadic inclusion body myositis: study design. Neuromuscular Disorders, 2019, 29, S41-S42.	0.6	2
131	Letter to the Editor (Matters arising from published papers). Rheumatology, 2019, 59, 261-262.	1.9	0
132	Role of diffusional kurtosis imaging in grading of brain gliomas: A diagnostic test accuracy systematic review and meta-analysis. Neuro-Oncology, 2019, 21, iv12-iv12.	1.2	0
133	25â€fPerformance of magnetic resonance imaging in the diagnosis of axial spondyloarthritis: a systematic literature review. Rheumatology, 2019, 58, .	1.9	0
134	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2019, 78, 1550-1558.	0.9	171
135	How to investigate: Early axial spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101427.	3.3	13
136	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Annals of the Rheumatic Diseases, 2019, 78, 996-1002.	0.9	81
137	Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis. Muscle and Nerve, 2019, 60, 161-168.	2.2	8
138	Performance of magnetic resonance imaging in the diagnosis of axial spondyloarthritis: a systematic literature review. Rheumatology, 2019, 58, 1955-1965.	1.9	25
139	Recommendations for acquisition and interpretation of MRI of the spine and sacroiliac joints in the diagnosis of axial spondyloarthritis in the UK. Rheumatology, 2019, 58, 1831-1838.	1.9	35
140	Community exercise is feasible for neuromuscular diseases and can improve aerobic capacity. Neurology, 2019, 92, e1773-e1785.	1.1	37
141	Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database. Arthritis Care and Research, 2019, 71, 1317-1325.	3.4	41
142	SAT0307â€...LONG-TERM ASSOCIATION BETWEEN DISEASE ACTIVITY MEASURED BY ASDAS AND PHYSICAL FUNCTION IN A LARGE EARLY AXIAL SPONDYLOARTHRITIS COHORT. , 2019, , .		0
143	THU0359â€...WHAT IS THE LEVEL OF AGREEMENT BETWEEN LOCAL AND CENTRAL READERS IN THE DETECTION OF ACTIVE AND STRUCTURAL LESIONS ON MRI TYPICAL OF AXIAL SPONDYLOARTHRITIS? DATA FROM THE ASAS CLASSIFICATION COHORT STUDY. , 2019, , .		0
144	PTH-123â€...Is axial spondyloarthritis in IBD different to axial spondyloarthritis without IBD?. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
145	SAT0327â€¦SEGMENTAL RELATIONSHIP BETWEEN MOBILITY, STRUCTURAL DAMAGE AND DISEASE ACTIVITY IN AXIAL SPONDYLOARTHRITIS. , 2019, , .		0
146	FRIO419â€¦OUTCOMES OF DOSE REDUCTION OF TNF-INHIBITORS IN AXIAL SPONDYLOARTHRITIS AT 24 MONTHS. , 2019, , .		0
147	THU0358â€¦DEVELOPMENT OF A SET OF ASAS QUALITY STANDARDS FOR ADULTS WITH AXIAL SPONDYLOARTHRITIS. , 2019, , .		0
148	THU0361â€¦DIAGNOSTIC PERFORMANCE OF MRI LESIONS IN THE SACROILIAC JOINTS ACCORDING TO UPDATED ASAS LESION DEFINITIONS: A CENTRAL READER ASSESSMENT OF MRI SCANS FROM THE ASSESSMENTS IN SPONDYLOARTHRITIS CLASSIFICATION COHORT. , 2019, , .		1
149	THU0366â€¦MAGNETIC RESONANCE IMAGING IN COMPARISON WITH CONVENTIONAL RADIOGRAPHY FOR DETECTION OF STRUCTURAL CHANGES TYPICAL FOR SPA â€œ DATA FROM THE ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS) COHORT. , 2019, , .		0
150	PTH-122â€¦Faecal calprotectin suggests presence of gut inflammation in axial spondyloarthritis without IBD. , 2019, , .		0
151	Treat-to-target in axial spondyloarthritis: gold standard or foolsâ€™ gold?. Current Opinion in Rheumatology, 2019, 31, 344-348.	4.3	19
152	Performance of referral strategies for spondyloarthritis: a population-based nationwide study. Rheumatology, 2019, 58, 1086-1094.	1.9	5
153	Biologics for treating axial spondyloarthritis. Expert Opinion on Biological Therapy, 2018, 18, 641-652.	3.1	20
154	Update on outcome assessment in myositis. Nature Reviews Rheumatology, 2018, 14, 303-318.	8.0	100
155	Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Annals of the Rheumatic Diseases, 2018, 77, 1539-1540.	0.9	159
156	Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Annals of the Rheumatic Diseases, 2018, 77, 699-705.	0.9	98
157	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 2018, 77, 3-17.	0.9	484
158	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Annals of the Rheumatic Diseases, 2018, 77, 30-39.	0.9	183
159	AB0868â€¦Lumbar muscles stiffness in patients with axial spondyloarthritis is altered in comparison with healthy subjects. , 2018, , .		1
160	AB0867â€¦Axial spondyloarthritis posture assessment using inertial sensors. , 2018, , .		1
161	Role of diffusional kurtosis imaging in grading of brain gliomas: a protocol for systematic review and meta-analysis. BMJ Open, 2018, 8, e025123.	1.9	6
162	Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. Frontiers in Medicine, 2018, 5, 40.	2.6	26

#	ARTICLE	IF	CITATIONS
163	Translating discovery science into treatments for patients: observational cohort studies at the MRC Centre for Neuromuscular Diseases. <i>Neuromuscular Disorders</i> , 2018, 28, S37.	0.6	0
164	Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1- $\beta$ autoantibodies in adult patients with myositis. <i>Arthritis Research and Therapy</i> , 2018, 20, 117.	3.5	16
165	FRI0202...Inertial motion sensors using the vimove <sup>®</sup> system is a valid method to assess spinal mobility in patients with axial spondyloarthritis. , 2018, , .		1
166	FRI0170...Consensus definitions for mri lesions in the sacroiliac joints of patients with axial spondyloarthritis: first analysis from the assessments in spondyloarthritis international society (ASAS) classification cohort. , 2018, , .		1
167	THUR 219...Myopathic manifestations in haematological conditions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A31.3-A31.	1.9	2
168	AB0866...Advanced metrology in patients with axial spondyloarthritis: lumbar or thoracic+lumbar measurements for spinal mobility assessment?. , 2018, , .		0
169	FRI0169...First validation of consensus definitions for mri lesions in the sacroiliac joint by the assessments in spondyloarthritis international society (ASAS) mri group. , 2018, , .		0
170	THU0276...Mri lesion definitions in axial spondyloarthritis: a consensus reappraisal from the assessments in spondyloarthritis international society (ASAS). , 2018, , .		1
171	FRI0209...Recommendations for acquisition and considerations for interpretation of mri of the spine and sacroiliac joints in the investigation of axial spondyloarthritis in the uk. , 2018, , .		0
172	OPO247...Performance of referral strategies for spondyloarthritis: a population-based nationwide study. , 2018, , .		0
173	OPO249...The contribution of structural mri lesions to detection of sacroiliitis in patients in the assessments in spondyloarthritis international society (ASAS) classification cohort. , 2018, , .		1
174	SAT0673...Magnetic resonance imaging in the diagnosis of axial spondyloarthritis: a systematic literature review. , 2018, , .		0
175	The impact of patient global assessment in the definition of remission as a predictor of long-term radiographic damage in patients with rheumatoid arthritis: protocol for an individual patient data meta-analysis. <i>Acta Reumatol<sup>3</sup>gica Portuguesa</i> , 2018, 43, 52-60.	0.2	5
176	The role of imaging in evaluating patients with idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 114, 74-81.	0.8	4
177	The Use of Analgesic and Other Pain-Relief Drugs to Manage Chronic Low Back Pain: Results from a National Survey. <i>Pain Practice</i> , 2017, 17, 353-365.	1.9	26
178	Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. <i>Arthritis and Rheumatology</i> , 2017, 69, 1090-1099.	5.6	41
179	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 978-991.	0.9	1,220
180	Cytosolic 5 <sup>2</sup> -nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 862-868.	0.9	71

#	ARTICLE	IF	CITATIONS
181	Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. <i>RMD Open</i> , 2017, 3, e000430.	3.8	28
182	Evaluating the benefits of community based aerobic training on the physical health and well-being of people with neuromuscular disease. <i>Neuromuscular Disorders</i> , 2017, 27, S43.	0.6	0
183	OP0023 Four-year imaging outcomes in axial spondyloarthritis patients treated with certolizumab pegol, including patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. , 2017, , .		2
184	THU0685 Asas health index for patients with spondyloarthritis: translation into portuguese, validation, and reliability. , 2017, , .		1
185	Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. <i>Nature Communications</i> , 2017, 8, 1859.	12.8	102
186	Reversible endogenous downregulation of myostatin pathway in wasting neuromuscular diseases explains challenges of anti-myostatin therapeutic approaches. <i>Neuromuscular Disorders</i> , 2017, 27, S97-S98.	0.6	0
187	Myostatin expression levels in neuromuscular diseases participates in anti-myostatin clinical failure. <i>Neuromuscular Disorders</i> , 2017, 27, S231.	0.6	0
188	FR10126 Aiming for remission according to any of the rheumatoid arthritis disease activity indices is more important for physical function than the actual choice of index: a longitudinal analysis in a clinical practice setting (meteor cohort). , 2017, , .		0
189	SAT0718-HPR Influence of patient global assessment on the disease activity assessment in patients with rheumatoid arthritis: a meteor cross-sectional study. , 2017, , .		0
190	Predictors of response to TNF blockers in patients with polyarticular psoriatic arthritis. <i>Acta Reumatológica Portuguesa</i> , 2017, 42, 55-65.	0.2	4
191	Translation and cross-cultural adaptation of the ASAS Health Index and ASAS Environmental Factors Item Set into European Portuguese Language. <i>Acta Reumatológica Portuguesa</i> , 2017, 42, 256-262.	0.2	2
192	Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt a national health survey. <i>RMD Open</i> , 2016, 2, e000166.	3.8	133
193	Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. <i>Neurobiology of Aging</i> , 2016, 47, 218.e1-218.e9.	3.1	40
194	Targeting protein homeostasis in sporadic inclusion body myositis. <i>Science Translational Medicine</i> , 2016, 8, 331ra41.	12.4	99
195	Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , 2016, 18, 156.	3.5	4
196	SAT0525 The Use of Analgesic and Other Pain Relief Drugs To Manage Chronic Low Back Pain Results from A National Survey: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 859.2-859.	0.9	0
197	AB1069 The Educational Needs of People with Spondyloarthropathies (AS and PSA): A Cross-Sectional Study: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1267.2-1267.	0.9	0
198	Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatology. <i>RMD Open</i> , 2016, 2, e000240.	3.8	14

#	ARTICLE	IF	CITATIONS
199	Sacroiliac joint radiographic progression " speed and determinants. Nature Reviews Rheumatology, 2016, 12, 380-382.	8.0	3
200	Disease specificity of autoantibodies to cytosolic 5 $\alpha$ -nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Annals of the Rheumatic Diseases, 2016, 75, 696-701.	0.9	116
201	Prevalence and social burden of active chronic low back pain in the adult Portuguese population: results from a national survey. Rheumatology International, 2016, 36, 183-197.	3.0	55
202	Measurements, composite scores and the art of "cutting-off"™. Annals of the Rheumatic Diseases, 2016, 75, 787-790.	0.9	15
203	MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurology, The, 2016, 15, 65-77.	10.2	256
204	MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2016, 75, 1486-1493.	0.9	103
205	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Annals of the Rheumatic Diseases, 2016, 75, 1558-1566.	0.9	127
206	Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Annals of the Rheumatic Diseases, 2016, 75, 1016-1023.	0.9	188
207	OP0052...Prevalence and Physical and Mental Health Patterns of Rheumatic and Musculoskeletal Diseases in Portugal: Results from EpiReumaPt, A National Health Survey. Annals of the Rheumatic Diseases, 2015, 74, 86.2-86.	0.9	0
208	SAT0236...Prevalence of Comorbidities and Evaluation of Their Screening in Spondyloarthritis: Results of the International Cross-Sectional ASAS-Comospa Study. Annals of the Rheumatic Diseases, 2015, 74, 743.4-744.	0.9	2
209	Study design of a prospective natural history study in sporadic inclusion body myositis (sIBM). Neuromuscular Disorders, 2015, 25, S238.	0.6	0
210	OP0041...MRI Inflammation and Fat Deposition Both Contribute to Syndesmophyte Formation at the Same Site: A Multi-Level Analysis in Patients with Ankylosing Spondylitis. Annals of the Rheumatic Diseases, 2015, 74, 81.2-82.	0.9	0
211	Genetic advances in sporadic inclusion body myositis. Current Opinion in Rheumatology, 2015, 27, 586-594.	4.3	8
212	The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis. Neurobiology of Aging, 2015, 36, 1766.e1-1766.e3.	3.1	16
213	2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Annals of the Rheumatic Diseases, 2015, 74, 8-13.	0.9	223
214	Brief Report: Calculating the Ankylosing Spondylitis Disease Activity Score If the Conventional C-reactive Protein Level Is Below the Limit of Detection or If High Sensitivity C-reactive Protein Is Used: An Analysis in the DESIR Cohort. Arthritis and Rheumatology, 2015, 67, 408-413.	5.6	50
215	OP0171...Achievement of Remission of Inflammation in the Spine and Sacroiliac Joints Measured by Magnetic Resonance Imaging (MRI) in Patients with Axial Spondyloarthritis, and Associations Between MRI and Clinical Remission, Over 96 Weeks of Treatment with Certolizumab Pegol. Annals of the Rheumatic Diseases. 2015, 74, 134.2-135.	0.9	1
216	EpiReumaPt- the study of rheumatic and musculoskeletal diseases in Portugal: a detailed view of the methodology. Acta Reumatológica Portuguesa, 2015, 40, 110-24.	0.2	26

#	ARTICLE	IF	CITATIONS
217	EpiReumaPt: how to perform a national population based study - a practical guide. Acta Reumatológica Portuguesa, 2015, 40, 128-36.	0.2	10
218	FRIO126...The Ankylosing Spondylitis Disease Activity Score (ASDAS): Defining the Best Calculation Method When the Conventional C-Reactive Protein (CRP) is below the Threshold of Detection - Results from the DESIR Cohort. Annals of the Rheumatic Diseases, 2014, 73, 427.1-427.	0.9	0
219	OP0133...Educational Needs of Young Clinicians and Researchers Working in Field of Rheumatology " Results from the Emeunet/Escet Survey. Annals of the Rheumatic Diseases, 2014, 73, 111.1-111.	0.9	0
220	Inclusion body myositis: clinical review and current practice. Clinical Practice (London, England), 2014, 11, 623-637.	0.1	0
221	Validation of the educational needs assessment tool as a generic instrument for rheumatic diseases in seven European countries. Annals of the Rheumatic Diseases, 2014, 73, 2122-2129.	0.9	37
222	Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2014, 28, 711-728.	3.3	29
223	Ongoing Developments in Sporadic Inclusion Body Myositis. Current Rheumatology Reports, 2014, 16, 477.	4.7	18
224	Sporadic inclusion body myositis: the genetic contributions to the pathogenesis. Orphanet Journal of Rare Diseases, 2014, 9, 88.	2.7	28
225	Sporadic inclusion body myositis. Current Opinion in Neurology, 2014, 27, 591-598.	3.6	18
226	Frequency and circumstances of falls in people with inclusion body myositis: a questionnaire survey to explore falls management and physiotherapy provision. Physiotherapy, 2014, 100, 61-65.	0.4	14
227	SP0067...How to Develop Meaningful Indices from Scratch (E.G. ASDAS). Annals of the Rheumatic Diseases, 2014, 73, 18.3-18.	0.9	0
228	Is it time to replace BASDAI with ASDAS?. Nature Reviews Rheumatology, 2013, 9, 388-390.	8.0	29
229	Longitudinal observational study of sporadic inclusion body myositis: Implications for clinical trials. Neuromuscular Disorders, 2013, 23, 404-412.	0.6	63
230	Anti-TNF and new bone formation in ankylosing spondylitis - the controversy continues. Arthritis and Rheumatism, 2013, 65, n/a-n/a.	6.7	24
231	Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype. Annals of the Rheumatic Diseases, 2013, 72, 1104-1107.	0.9	18
232	Update in inclusion body myositis. Current Opinion in Rheumatology, 2013, 25, 763-771.	4.3	34
233	New developments in the diagnosis and treatment of axial spondyloarthritis. Clinical Investigation, 2013, 3, 153-171.	0.0	0
234	FRIO291...MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a TNF inhibitor.. Annals of the Rheumatic Diseases, 2013, 71, 412.2-412.	0.9	1

#	ARTICLE	IF	CITATIONS
235	THU0283â€¦Predictive factors of response at 12 weeks in patients with ankylosing spondylitis starting biological therapies - results from the portuguese register - REUMA.PT.: Annals of the Rheumatic Diseases, 2013, 71, 251.1-251.	0.9	0
236	097â€¦Valosin Containing Protein (VCP) and Myofibrillar Myopathies (MFM) genes' mutations are not associated with sporadic Inclusion Body Myositis (sIBM). Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.45-e1.	1.9	0
237	Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Annals of the Rheumatic Diseases, 2012, 71, 809-816.	0.9	148
238	Who are the young professionals working in the field of rheumatology in Europe and what are their needs? An EMEUNET (EMerging EUlar NETwork) survey. Annals of the Rheumatic Diseases, 2012, 71, 1432-1433.	0.9	10
239	MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Annals of the Rheumatic Diseases, 2012, 71, 2002-2005.	0.9	87
240	MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2012, 71, 369-373.	0.9	126
241	1130â€¦Clinical features and clinical course of sporadic inclusion body myositis (IBM): a prospective cohort study: IBM-net. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.101-e1.	1.9	0
242	Portuguese recommendations for the use of biological therapies in patients with axial spondyloarthritis-December 2011 update. Acta ReumatolÃ³gica Portuguesa, 2012, 37, 40-7.	0.2	1
243	HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis. Annals of the Rheumatic Diseases, 2011, 70, 1930-1936.	0.9	131
244	Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Annals of the Rheumatic Diseases, 2011, 70, 47-53.	0.9	589
245	P71 A randomised, double-blinded, placebo-controlled pilot study assessing the safety and tolerability of Arimoclomol in sporadic inclusion body myositis (IBM). Neuromuscular Disorders, 2011, 21, S27.	0.6	0
246	P79 The natural history of sporadic inclusion body myositis: development of an electronic database IBM net. Neuromuscular Disorders, 2011, 21, S29.	0.6	0
247	Endorsement of Definitions of Disease Activity States and Improvement Scores for the Ankylosing Spondylitis Disease Activity Score: Results from OMERACT 10. Journal of Rheumatology, 2011, 38, 1502-1506.	2.0	52
248	How to measure disease activity in axial spondyloarthritis?. Current Opinion in Rheumatology, 2011, 23, 339-345.	4.3	51
249	Cross-cultural validation of the Educational Needs Assessment Tool in RA in 7 European countries. BMC Musculoskeletal Disorders, 2011, 12, 110.	1.9	49
250	The Value of Magnetic Resonance Imaging and Ultrasound in Undifferentiated Arthritis: A Systematic Review. Journal of rheumatology Supplement, The, 2011, 87, 31-37.	2.2	33
251	Algorithm for Identification of Undifferentiated Peripheral Inflammatory Arthritis: A Multinational Collaboration Through the 3e Initiative. Journal of rheumatology Supplement, The, 2011, 87, 54-58.	2.2	11
252	The Value of Conventional Radiographs in Undifferentiated Arthritis: A Systematic Review. Journal of rheumatology Supplement, The, 2011, 87, 26-30.	2.2	4

#	ARTICLE	IF	CITATIONS
253	Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 15-24.	0.9	68
254	A stratified model for health outcomes in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1758-1764.	0.9	65
255	Selecting men for bone densitometry: performance of osteoporosis risk assessment tools in Portuguese men. <i>Osteoporosis International</i> , 2010, 21, 977-983.	3.1	15
256	Methotrexate treatment in rheumatoid arthritis: management in clinical remission, common infection and tuberculosis. Results from a systematic literature review. <i>Clinical Rheumatology</i> , 2010, 29, 629-635.	2.2	13
257	Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1465-1470.	0.9	244
258	On restoring data coherence in a GALS system for medical imaging. , 2010, , .		2
259	Applying science in practice: the optimization of biological therapy in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2010, 12, 220.	3.5	14
260	Portuguese guidelines for the use of biological agents in rheumatoid arthritis - March 2010 update. <i>Acta ReumatolÃ³gica Portuguesa</i> , 2010, 35, 95-8.	0.2	4
261	Increased prevalence of allergic sensitisation in rheumatoid arthritis patients treated with anti-TNF±. <i>Joint Bone Spine</i> , 2009, 76, 508-513.	1.6	3
262	Sporadic inclusion body myositis: an unsolved mystery. <i>Acta ReumatolÃ³gica Portuguesa</i> , 2009, 34, 161-82.	0.2	10
263	An overview of the Clear-PEM breast imaging scanner. , 2008, , .		6
264	Experimental validation and performance analysis of the clear-PEM data acquisition electronics. , 2008, , .		4
265	Arthritis and X-linked agammaglobulinemia. <i>Acta ReumatolÃ³gica Portuguesa</i> , 2008, 33, 464-7.	0.2	6
266	Overview of the ECAL off-detector electronics of the CMS experiment. <i>IEEE Transactions on Nuclear Science</i> , 2005, 52, 1918-1924.	2.0	7
267	Experience with telemedicine amongst rheumatology clinicians during the COVID-19 pandemic: an international survey. <i>Rheumatology Advances in Practice</i> , 0, , .	0.7	9
268	Minimal Impact of the <sc>COVID</sc> â€19 Pandemic on Disease Activity and <sc>Healthâ€™Related</sc> Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b <sc>Openâ€™Label</sc> Extension Study. <i>ACR Open Rheumatology</i> , 0, , .	2.1	1